Cancer therapy developer ADC has attracted $76m to extend its series E round, after AstraZeneca supported a $200m initial tranche in 2017.

Switzerland-based oncology drug developer ADC Therapeutics yesterday received $76m in additional series E financing to bring the round, already backed by pharmaceutical firm AstraZeneca, to a $276m close. The additional capital was supplied by unnamed existing and new investors. The first tranche was led by private equity firm Auven Therapeutics in late 2017 and, apart…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.